BEIJING - Like a stone being thrown into a pool of calm water, the China FDA released on March 9 “Document 51, Reform Plans for Chemical Drug Registration”, stirring up immediate reactions from the pharma industry.
Although the CFDA had in late 2015 decided to narrow the definition of "new drugs", the agency provides further details...
Welcome to Scrip
Create an account to read this article
Already a subscriber?